Tag: Vascepa

Amarin Reports Overview of Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) and Eicosapentaenoic Acid (EPA) Presented at the American Heart Association Scientific Sessions 2021

VASCEPA/VAZKEPA found in prespecified and post hoc analyses to reduce total ischemic events by 32% in patients with prior PAD DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 16, 2021 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today reported an overview of new data relating to VASCEPA®/VAZKEPA (icosapent ethyl) presented at the […]

Amarin Outlines New Go-to-Market Strategy to Accelerate VASCEPA® (Icosapent Ethyl) Growth in U.S.

Enables Amarin to Drive Additional Demand, Improve Patient Access & Education and Secure Proper Fulfillment and Reimbursement DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ: AMRN) today outlined its new Go-to-Market strategy to accelerate growth of VASCEPA® (icosapent ethyl) in the United States, which […]

Amarin Reports Data from REDUCE-IT® Showing VASCEPA®/VAZKEPA (Icosapent Ethyl) Significantly Reduces Ischemic Events in Patients with Prior Heart Attacks Presented in Late Breaking Science Session at ESC Congress 2021, Organized by the European Society of Cardiology

VASCEPA found in prespecified and post hoc analyses to reduce first and total primary endpoints by 26% and 35%, respectively, in patients with prior Myocardial Infarction DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 23, 2021 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today announced that data adding to the growing body […]

Amarin Highlights Multiple Scientific Findings for VASCEPA® (Icosapent Ethyl) and Its Unique Active Ingredient at the American College of Cardiology’s 70th Annual Scientific Session

REDUCE-IT® patients experienced substantial cardiovascular (CV) risk reduction with icosapent ethyl regardless of the presence or degree of dyslipidemia, as defined by various high TG plus low HDL-C levels Patients randomized to VASCEPA in EVAPORATE trial, in analyses of percent atheroma volume (PAV), had 55% lower coronary total plaque (TP) PAV […]

VASCEPA® (Icosapent Ethyl) Found in Prespecified and Post Hoc Analyses to Significantly Reduce Stroke in At-Risk Patients in Analyses of Landmark REDUCE-IT® Study Presented at International Stroke Conference 2021

28% and 32% significant reductions in first and total strokes, respectively, demonstrated with VASCEPA compared to placebo, as well as reductions in first and total ischemic strokes each by 36%, without increasing hemorrhagic stroke, in statin-treated patients with elevated cardiovascular risk Consistent reductions in overall stroke and in ischemic stroke […]

Matinas BioPharma Announces Topline Results from ENHANCE-IT Study of LYPDISO™ Against Vascepa®

– LYPDISO™ demonstrated a statistically significant 46% relative percent increase in EPA change from baseline over Vascepa® – – LYPDISO™ demonstrated a 39% relative difference in response over Vascepa in TG reduction – – Primary endpoint of percent change from baseline to end of treatment in triglycerides in the pharmacodynamic population did not meet […]

Amarin Shares Topline Data from Partner’s Pivotal Phase 3 Study of VASCEPA® (Icosapent Ethyl) in Mainland China

Significant Reduction in Triglyceride Levels Without Low-Density Lipoprotein Cholesterol (LDL-C) Increase Compared to Placebo and Safety Profile Similar to Placebo Achieved with 4 Grams Per Day Dose of Icosapent Ethyl in Chinese Patients with Very High Triglycerides (>500 mg/dL) Results Support Upcoming Submission by Partner, Edding, Seeking Regulatory Approval in China DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 19, 2020 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today shared positive, statistically […]

VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Coronary Artery Bypass Grafting (CABG) Procedures in Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study Presented at American Heart Association’s Virtual Scientific Sessions 2020

VASCEPA®, compared with placebo, significantly reduced primary composite first and total major adverse cardiovascular events (MACE) in post hoc exploratory analyses of patients with a history of CABG by 24% and 36%, respectively, and key secondary composite first hard MACE, comprised of heart attacks, stroke and cardiovascular death, by 31% Administration of VASCEPA resulted in […]

New VASCEPA® (Icosapent Ethyl)-Related Scientific Findings to Be Presented at American Heart Association’s Virtual Scientific Sessions 2020

Amarin-Supported Research and Analyses from Academic Collaborators to Be Featured in Eight Presentations, Including REDUCE-IT® CABG (Coronary Artery Bypass Graft) Results and Additional Mechanism of Action Insights DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today announced that new scientific findings that add […]

VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Cardiovascular Events in Patients with Compromised Renal Function at Baseline in Prespecified and Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study Presented at American Society of Nephrology (ASN) Kidney Week 2020

Patients with decreased renal function prior to treatment with VASCEPA or placebo had higher rates of cardiovascular events than the overall population studied in REDUCE-IT REDUCE-IT patients with decreased renal function prior to treatment showed similarly favorable relative risk reductions and numerically greater absolute risk reductions in cardiovascular events in […]